evipedia.ai
← Back

Omaveloxolone for Health & Longevity

Evidence Review created on 10/10/2026 using AI4L / Opus 5.5

Also known as: Skyclarys, RTA 408, RTA-408, BIIB141

Motivation

Omaveloxolone (brand name Skyclarys) is a prescription oral medication built from a plant-derived compound family. It works by switching on a master control system that cells use to defend themselves against oxidation damage and inflammation. It draws attention because it is the first medication approved for Friedreich’s ataxia, a rare inherited disease that steadily damages nerves, coordination and the heart, and because that same defense system is a prominent target in the biology of aging.

The medication grew out of an earlier related compound developed for kidney disease and has also been tested in several other conditions before reaching approval. Interest from people focused on healthy aging comes from the idea that strengthening the body’s own defenses, rather than taking antioxidant supplements, might slow age-related decline, and from the fact that this is one of very few approved medications that act directly on that system.

This review examines what is known about omaveloxolone’s benefits in Friedreich’s ataxia, its risks and interactions, how it is dosed and monitored, and whether any human data bear on its use for general health and longevity by people without the disease.

Benefits - Risks - Protocol - Conclusion

Overviews of omaveloxolone’s clinical development, its chemistry, and the antioxidant-switch biology behind both its longevity appeal and its main caveat.

Beyond Rhonda Patrick’s episode on the shared NRF2 pathway, no directly relevant content was found from Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io; these longevity platforms have not covered this prescription medication for a rare neurological disease, so academic reviews fill the rest of the list.

Grokipedia

Omaveloxolone

An AI-written encyclopedia entry summarizing omaveloxolone’s chemistry, mechanism, pivotal trials, approvals and adverse effects; useful for quick orientation, though its claims need checking against primary sources.

Examine

No Examine article on omaveloxolone exists. Examine.com does not typically cover prescription medications.

ConsumerLab

No ConsumerLab article on omaveloxolone exists. ConsumerLab does not typically cover prescription medications.

Systematic Reviews

Systematic reviews and meta-analyses covering omaveloxolone, mostly as part of Friedreich’s ataxia treatment overall.

No systematic review or meta-analysis addresses omaveloxolone’s principal risks — liver enzyme, cholesterol and heart-strain marker changes — beyond pooled adverse-event counts.

Mechanism of Action

Omaveloxolone binds a reactive site on KEAP1, so Nrf2 escapes destruction, enters the cell nucleus and switches on protective genes such as NQO1 and HO-1 (antioxidant and detoxifying enzymes) and those that make glutathione (the main antioxidant produced inside cells) (Lee, 2023; Reisman et al., 2019, by manufacturer scientists). It also suppresses NF-κB (nuclear factor kappa B, a master switch for inflammatory genes). In Friedreich’s ataxia, lack of frataxin (a mitochondrial protein needed to handle iron) blunts Nrf2 signaling, so restoring it is thought to protect nerve and heart cells from oxidative damage and ferroptosis (iron-driven cell death) (Lynch et al., 2019, a manufacturer-sponsored trial; Portillo-Carrasquer et al., 2026).

Competing readings exist. The U.S. label states that how the medication benefits patients is unknown (Skyclarys prescribing information). Nrf2 activation can also shield cancer cells (Lau et al., 2008), and in mice with severe frataxin-related heart disease it improved pumping without extending survival (Salinas et al., 2025).

  • Half-life: about 57 hours (range 32–90), allowing once-daily dosing (Skyclarys prescribing information).
  • Selectivity: acts on a signaling hub (KEAP1–Nrf2, plus NF-κB) rather than a single receptor.
  • Tissue distribution: 97% bound to blood proteins (Skyclarys prescribing information) yet widely taken up by tissues, reaching liver, lung and brain in monkeys (Reisman et al., 2019).
  • Metabolism: mainly by CYP3A4 (the liver enzyme that clears about half of all drugs), with minor roles for CYP2C8 and CYP2J2 (other drug-clearing liver enzymes); about 92% leaves in feces (Skyclarys prescribing information).

Historical Context & Evolution

Omaveloxolone descends from oleanolic acid, a plant triterpenoid, via Reata Pharmaceuticals’ synthetic derivatives (Lee, 2023; Cordaro et al., 2025). Its predecessor, bardoxolone methyl, failed in diabetic kidney disease when the Reata-funded BEACON trial stopped early over excess heart-failure events, which the sponsor traced to fluid retention (de Zeeuw et al., 2013; Chin et al., 2014).

Omaveloxolone was first tested in advanced cancer, without tumor shrinkage (Creelan et al., 2017), then as a lotion against radiation dermatitis (skin injury from radiotherapy) (NCT02142959), as eye drops after cataract surgery (NCT02128113), neither meeting its main goal, and in mitochondrial myopathy (muscle disease from faulty cellular energy factories), where peak exercise capacity did not change (Madsen et al., 2020); all were manufacturer-sponsored.

Friedreich’s ataxia became the lead use. MOXIe’s dose-finding part found the strongest biological response at 80–160 mg/day (Lynch et al., 2019), and the placebo-controlled part showed less neurological worsening at 48 weeks (Lynch et al., 2021); both were Reata-sponsored. The U.S. Food and Drug Administration (FDA) approved it in February 2023, based on that trial plus a post hoc (decided after the trial) comparison with untreated patients (FDA approval announcement); the European Union followed in February 2024, noting uncertainties such as the small pivotal trial (European Medicines Agency product page). Since then, a Cochrane review found pooled drugs barely changed ataxia scores (Lyons et al., 2026), while real-world patients worsened more slowly than expected (Ali et al., 2026). Longevity interest rests on Nrf2’s role in aging biology, untested in people.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: all randomized trials of omaveloxolone in Friedreich’s ataxia come from a single research group (Lynch and colleagues’ MOXIe trials), and longer-term data are uncontrolled or compared with external untreated patients.

Medium 🟩 🟩

Slower neurological decline in Friedreich’s ataxia ⚠️ Conflicted

In MOXIe part 2, a 48-week randomized controlled trial (RCT, participants assigned by chance) in 103 people, Lynch’s group found better mFARS (modified Friedreich’s Ataxia Rating Scale, a 93-point clinician exam) scores than placebo (Lynch et al., 2021); the gap persisted versus matched untreated patients over 3 years (Lynch et al., 2024, with manufacturer co-authors). A Cochrane review pooling several drugs found little effect (Lyons et al., 2026); real-world cohorts kept worsening, though slower than the untreated course (Ali et al., 2026). Net: modest slowing, not yet independently replicated.

Magnitude: mFARS 2.40 points lower than placebo at 48 weeks (95% CI, the range likely to contain the true effect, −4.31 to −0.50) (Lynch et al., 2021); over 3 years, 3.0 versus 6.6 points of worsening in matched untreated patients (difference −3.6; external comparison, not randomized) (Lynch et al., 2024).

Better preserved daily functioning in Friedreich’s ataxia

In MOXIe part 2, the FA-ADL (Friedreich’s Ataxia Activities of Daily Living, a patient-reported scale of tasks such as dressing and eating) numerically favored omaveloxolone, but because an earlier endpoint in the testing order failed, the result is only nominally significant (Lynch et al., 2021). The evidence comes from one manufacturer-sponsored trial by Lynch’s group, and it is distinct from the clinician-scored exam above.

Magnitude: FA-ADL 1.30 ± 0.63 points lower than placebo at 48 weeks (−0.17 ± 0.45 with omaveloxolone versus +1.14 ± 0.42 with placebo; nominally significant; values ± standard error, a measure of an estimate’s precision); a post hoc analysis adjusting for baseline differences gave a difference of −1.50 points (Lynch et al., 2021).

Low 🟩

More efficient moderate-intensity exercise ⚠️ Conflicted

In the MOTOR RCT in mitochondrial myopathy (Madsen and colleagues), 160 mg lowered heart rate and blood lactate during moderate exercise (Madsen et al., 2020). Peak workload, the primary endpoint, was unchanged there and in MOXIe part 1 (Lynch et al., 2019). Net: exploratory efficiency gains without greater capacity.

Magnitude: At 160 mg, heart rate during moderate exercise 12.0 ± 4.6 beats per minute and lactate 1.4 ± 0.7 mmol/L lower than placebo at 12 weeks (exploratory; ± standard error) (Madsen et al., 2020); peak workload 0.9 ± 2.9 W versus placebo in Friedreich’s ataxia, not significant (Lynch et al., 2019).

Speculative 🟨

Slower biological aging

Nrf2 signaling is altered in long-lived animal models and linked to healthier aging (Bruns et al., 2015; Matsumaru & Motohashi, 2021). No study has tested omaveloxolone on lifespan or aging; the basis is mechanistic only.

Protection of the brain beyond Friedreich’s ataxia

In mice, omaveloxolone improved memory and reduced amyloid plaque (Alzheimer’s-type protein clumps) (Liu & Jia, 2025) and aided recovery after brain hemorrhage (Hu et al., 2022). No human data exist; the basis is animal only.

Protection of heart muscle

It improved heart contraction in frataxin-deficient mice (Salinas et al., 2025) and limited harmful remodeling in pressure-overloaded mouse hearts (Li et al., 2025). No controlled human heart outcomes exist; the basis is animal only.

Lower systemic inflammation

IL-6 (interleukin-6, an inflammatory signaling protein) fell over 24 weeks in an uncontrolled Italian cohort of 20 adults (Lima et al., 2025). IL-6 is no validated stand-in for outcomes; no controlled study exists.

Benefit-Modifying Factors

  • Genetic background: a longer GAA1 repeat (the size of the disease-causing DNA expansion in FXN, the frataxin gene) marks more severe disease; adjusting for it enlarged the measured treatment effect (Lynch et al., 2021). No drug-metabolism gene variants have been studied for benefit.
  • Baseline biomarkers and severity: trials enrolled mFARS 20–80; benefit in more advanced disease is untested. Ferritin and GGT (gamma-glutamyl transferase, a liver enzyme), both Nrf2-responsive, rose most at 80–160 mg, showing the medication reached its target (Lynch et al., 2019).
  • Sex: effects were numerically larger in men than women in MOXIe part 2 (Lynch et al., 2021); drug exposure does not differ by sex (Skyclarys prescribing information).
  • Pre-existing conditions: pes cavus (a high-arched foot deformity common in the disease) blunted measured gains; without it, mFARS improved 4.4 points versus placebo at 160 mg (Lynch et al., 2019). Advanced heart disease was excluded.
  • Age: the numerically largest effect was in participants under 18 (Lynch et al., 2021); no one aged 65 or older was studied, and healthy adults seeking longevity benefits have no data at all.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: each adverse effect rests on randomized data from a single research group (Lynch and colleagues’ MOXIe trials), with only uncontrolled cohorts and spontaneous reports from other groups.

Medium 🟥 🟥

Liver enzyme elevation

Omaveloxolone raises ALT and AST (alanine and aspartate aminotransferase, enzymes released by stressed liver cells), peaking within 12 weeks and returning to baseline within about 4 weeks of stopping, without bilirubin rises or Hy’s law cases (the standard pattern signaling serious drug-induced liver injury) in MOXIe part 2 (Lynch et al., 2021). An uncontrolled Italian cohort saw transient elevations in half of patients (Lima et al., 2025), and it is the strongest signal in U.S. adverse-event reports (Liu et al., 2025). Its mechanism is not established.

Magnitude: Elevated liver enzymes in 37% versus 2% with placebo (Skyclarys prescribing information); peak ALT at least 3 times the upper limit of normal in 29% versus 0% with placebo (Lynch et al., 2021).

Rise in artery-clogging cholesterol

In MOXIe part 2, cholesterol rose within 2 weeks and normalized within 4 weeks of stopping; LDL-C (low-density lipoprotein cholesterol, the main artery-clogging cholesterol) rose and HDL-C (high-density lipoprotein, “good” cholesterol) dipped (Skyclarys prescribing information). A Vienna cohort of 17 adults found a sustained rise in LDL-C and ApoB (apolipoprotein B, the protein on each artery-clogging particle), consistent with reduced liver clearance (Buchinger et al., 2026), while a 236-patient clinic cohort saw only mild cholesterol and LDL-C rises over 1 year (Gunther et al., 2025). Long-term cardiovascular consequences are unknown.

Magnitude: LDL-C increase from baseline in 16% versus 8% with placebo; mean LDL-C rise of 23.5 mg/dL and HDL-C fall of 5.3 mg/dL at 48 weeks in treated patients (placebo means not reported) (Skyclarys prescribing information); LDL-C up 35–50 mg/dL over 1 year (no control group) (Buchinger et al., 2026).

Raised heart-strain marker and fluid-overload concern ⚠️ Conflicted

BNP (B-type natriuretic peptide, a hormone released when the heart is strained) rose above normal more often with omaveloxolone in MOXIe part 2; the label calls the cause unclear (Skyclarys prescribing information). Related bardoxolone methyl increased heart-failure events in advanced kidney disease (de Zeeuw et al., 2013), linked to fluid retention (Chin et al., 2014). Uncontrolled cohorts found stable NT-proBNP (a related marker) (Lima et al., 2025) and unchanged BNP (Gunther et al., 2025). Net: a randomized signal, unconfirmed in practice.

Magnitude: BNP above 100 pg/mL with a rise from baseline in 14% versus 4% with placebo; BNP above 200 pg/mL in 4% of treated patients (placebo figure not reported) (Skyclarys prescribing information). With bardoxolone methyl, heart-failure hospitalization or death occurred in 96 versus 55 patients (hazard ratio, the relative event rate over time, 1.83; 95% CI 1.32 to 2.55) (de Zeeuw et al., 2013).

Gastrointestinal symptoms

Nausea, abdominal pain and diarrhea were more common with omaveloxolone, mostly within the first 12 weeks as tolerance developed, and were generally mild to moderate (Lynch et al., 2021); the label also reports more vomiting (Skyclarys prescribing information). Evidence comes from one manufacturer-sponsored trial by Lynch’s group.

Magnitude: Nausea 33% versus 13% with placebo; abdominal pain 29% versus 6%; diarrhea 20% versus 10%; vomiting 16% versus 12% (Skyclarys prescribing information).

Headache and fatigue

Headache and fatigue were more frequent with omaveloxolone in MOXIe part 2, clustering in the first 12 weeks before evening out with placebo (Lynch et al., 2021). Both were generally mild to moderate.

Magnitude: Headache 37% versus 25% with placebo; fatigue 24% versus 14% (Skyclarys prescribing information).

Reduced appetite and weight loss

Treated adults lost weight relative to baseline and placebo over 48 weeks, more so when overweight at entry (Lynch et al., 2021), and the label reports decreased appetite more often (Skyclarys prescribing information). For people with low muscle reserve, unintended weight loss is a concern; the mechanism is not established.

Magnitude: Decreased appetite 12% versus 4% with placebo (Skyclarys prescribing information); the trial report gives the direction of weight change but no figure in its text (Lynch et al., 2021).

Musculoskeletal pain and muscle spasms

For MOXIe part 2 (Lynch et al., 2021), the label’s adverse-reaction table shows musculoskeletal pain, muscle spasms and back pain more often with omaveloxolone than placebo (Skyclarys prescribing information). They were mostly mild to moderate; the mechanism is unknown.

Magnitude: Musculoskeletal pain 20% versus 15% with placebo; muscle spasms 14% versus 6%; back pain 13% versus 8% (Skyclarys prescribing information).

Influenza and throat pain

For MOXIe part 2, the label’s adverse-reaction table shows influenza and oropharyngeal pain (pain at the back of the throat) more often with omaveloxolone (Skyclarys prescribing information), while the trial report found no excess of upper respiratory tract infections (28% versus 29%) (Lynch et al., 2021). Whether Nrf2 activation alters immune defense in people is unknown.

Magnitude: Influenza 16% versus 6% with placebo; oropharyngeal pain 18% versus 6% (Skyclarys prescribing information).

Rash and hypersensitivity

For MOXIe part 2 (Lynch et al., 2021), the label’s adverse-reaction table shows rash more often with omaveloxolone, and post-approval reports added hypersensitivity reactions such as hives (Skyclarys prescribing information). Its mechanism is unknown.

Magnitude: Rash 10% versus 4% with placebo; post-approval hypersensitivity cases have no comparison group or denominator (Skyclarys prescribing information).

Low 🟥

Urinary, metabolic and heart-rhythm signals in post-marketing reports

An analysis of 820 U.S. adverse-event reports flagged urinary tract infection, diabetes, abnormal urine odor, atrial flutter (a fast heart rhythm) and urosepsis (urinary infection spreading to the blood) (Liu et al., 2025). Friedreich’s ataxia itself causes these problems, so the signals may reflect the disease.

Magnitude: Not quantified in available studies. Spontaneous reports have no denominator or comparison group, so no incidence or excess risk can be derived from them.

Speculative 🟨

Harm to pregnancy and offspring

In rats and rabbits, omaveloxolone caused embryo-fetal death, growth impairment and offspring learning deficits at exposures at or below human levels (Skyclarys prescribing information). Human pregnancy data are lacking; the basis is animal only.

Liver tumors in rats

A 2-year rat study found more bile-duct tumors in females at about twice human exposure, while a 26-week mouse study found none (Skyclarys prescribing information). The basis is animal only.

Cancer-shielding effect of sustained Nrf2 activation

Persistent Nrf2 activity helps some cancers survive and resist chemotherapy (Lau et al., 2008). Whether medication-driven activation promotes cancer in people is untested; the basis is mechanistic only.

Earlier death in female mice with severe cardiomyopathy

In frataxin-deficient mice with severe cardiomyopathy (heart-muscle disease), omaveloxolone did not prevent early death and accelerated it in females (Salinas et al., 2025). The basis is a single animal study.

Risk-Modifying Factors

  • Genetic variants: no pharmacogenetic (gene-based drug-response) data exist; inherited low or high CYP3A4/CYP3A5 activity (CYP3A5 is a related drug-clearing enzyme) could plausibly shift exposure and side effects (theoretical).
  • Baseline biomarkers: people with BNP above 200 pg/mL or clinically significant liver disease were excluded from the pivotal trial (Skyclarys prescribing information); high baseline LDL-C leaves less margin for the expected rise (theoretical).
  • Sex: women of reproductive potential face contraceptive failure and animal fetal-toxicity signals; female mice with severe cardiomyopathy died earlier on treatment (Salinas et al., 2025).
  • Pre-existing conditions: moderate liver impairment raises exposure up to 1.65-fold; heart failure and moderate-to-severe kidney impairment (untested) may add risk (Skyclarys prescribing information).
  • Age: drug exposure did not differ between ages 16 and 71, but no one aged 65 or older was in efficacy trials, so age-related heart, liver and drug-interaction risks are unstudied (Skyclarys prescribing information).

Key Interactions & Contraindications

  • Strong CYP3A4 inhibitors (drugs blocking CYP3A4: itraconazole, ketoconazole, clarithromycin, ritonavir): Avoid. Itraconazole tripled peak and quadrupled total exposure, raising adverse-reaction risk (Zahir et al., 2025, manufacturer-run); if unavoidable, the label cuts the dose to 50 mg with close monitoring (Skyclarys prescribing information).
  • Moderate CYP3A4 inhibitors (verapamil, diltiazem, fluconazole, erythromycin): Avoid. Verapamil raised exposure about 1.25-fold, increasing adverse-reaction risk (Zahir et al., 2025; Skyclarys prescribing information); if unavoidable, the label reduces the dose to 100 mg, then 50 mg if adverse reactions emerge.
  • Grapefruit and grapefruit juice: Avoid per label counseling; CYP3A4 inhibition is expected to raise exposure and side effects (Skyclarys prescribing information). No dedicated study exists.
  • Strong or moderate CYP3A4 inducers (drugs boosting CYP3A4: rifampin, carbamazepine, phenytoin, efavirenz): Avoid. Efavirenz lowered peak exposure 38% and total exposure 48%, likely reducing effectiveness (Zahir et al., 2025).
  • St John’s wort (supplement): Avoid (theoretical); the label names it as a product to discuss, and as a CYP3A4 inducer it is expected to lower omaveloxolone exposure and effectiveness (Skyclarys prescribing information). No direct study exists.
  • Hormonal contraceptives (combined oral contraceptives, patch, ring, implants, progestin-only oral contraceptives): Avoid relying on them. As a weak CYP3A4 inducer, omaveloxolone may cause contraceptive failure; the label advises a non-hormonal or added barrier method during use and 28 days after (Skyclarys prescribing information).
  • CYP3A4, CYP2C8 and transporter substrates (midazolam, repaglinide, rosuvastatin): Monitor for lost effect. Omaveloxolone lowered midazolam exposure about 45%, repaglinide 35% and rosuvastatin 30% (BCRP and OATP1B1 substrate; these are drug-carrying pumps) (Zahir et al., 2025; Skyclarys prescribing information).
  • Statins (cholesterol-lowering drugs: atorvastatin, simvastatin): Monitor. These CYP3A4-cleared statins may lose some effect (theoretical) just as omaveloxolone raises LDL-C; rechecking lipids after starting either medication detects this.
  • Medications without a meaningful interaction (digoxin, metformin, gemfibrozil): No dose change needed; studies found no clinically significant exposure change (Zahir et al., 2025).
  • Medications that prolong heart-rhythm timing (sotalol, citalopram): Monitor only as usual (theoretical); no combination study exists, but a 450 mg dose alone did not cause clinically significant QTc prolongation (QTc is a heart-rhythm timing interval on the electrocardiogram) (Zahir et al., 2025, manufacturer-run).
  • Over-the-counter weak CYP3A4 inhibitors (cimetidine): No adjustment needed; the label expects no clinically significant change with weak CYP3A4 inhibitors (Skyclarys prescribing information).
  • Over-the-counter acetaminophen (high doses) and alcohol: Caution (theoretical). Both stress the liver and could add to omaveloxolone’s enzyme elevations; spacing liver tests around heavy use clarifies results.
  • Supplements with additive Nrf2 activation (sulforaphane, curcumin) and dimethyl fumarate (a multiple sclerosis drug): Monitor (theoretical). Overlapping pathway stimulation could amplify both effects and side effects; no interaction study exists.
  • Supplements that inhibit CYP3A4 or stress the liver (goldenseal, high-dose green tea extract): Caution (theoretical). Goldenseal may raise omaveloxolone exposure; concentrated green tea extract can independently raise liver enzymes.
  • Food (other intervention): Avoid dosing with meals. A high-fat meal raised peak exposure about 350% and total exposure 15%, which could worsen side effects (Skyclarys prescribing information); manufacturer food-effect modeling explains why (Pepin et al., 2024).

Populations who should avoid Omaveloxolone:

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Scheduled liver testing: ALT, AST and bilirubin before starting, monthly for 3 months, then periodically; stop if above 5 times normal, or above 3 times with bilirubin rise (Skyclarys prescribing information), preventing progression of liver enzyme elevation to injury.
  • Stepwise restart after a liver pause: experts suggest repeat testing after 2 weeks, then restarting with stepwise dose increases and testing every 2 weeks for about 3 months (Perlman et al., 2025, funded by the manufacturer), limiting recurrent enzyme elevation.
  • Fluid-overload watch: BNP before starting, with the label naming weight gain of 3 lb in a day or 5 lb in a week, swelling, palpitations or breathlessness as triggers for evaluation (Skyclarys prescribing information), catching heart strain early.
  • Lipid surveillance: lipids before starting and periodically (Skyclarys prescribing information); adding ApoB at 2–3 months, then every 6–12 months, with guideline-based treatment limits cardiovascular risk from the LDL-C rise.
  • Fasting administration: taking the dose at least 1 hour before or 2 hours after eating (Skyclarys prescribing information) avoids the food-driven exposure spike that could worsen side effects.
  • Interaction screening: a review of all prescriptions, grapefruit intake and supplements such as St John’s wort before starting and with each new prescription prevents toxic exposure rises or loss of effect.
  • Non-hormonal contraception: a copper intrauterine device or added condoms during use and for 28 days after stopping (Skyclarys prescribing information) prevents unplanned pregnancy from contraceptive failure.
  • Early-tolerability support: small, regular meals outside the dosing window and hydration during the first 12 weeks ease nausea, headache and fatigue, which mostly fade after that period.
  • Weight and nutrition tracking: monthly weight and adequate protein intake guard against unintended weight and muscle loss.

Therapeutic Protocol

Doses are cited to their source; other parameters without a citation (e.g., timing, titration steps, cycling) reflect common practice.

  • Standard regimen: 150 mg (three 50 mg capsules) orally once daily, as in MOXIe part 2 and the label (Skyclarys prescribing information); developed by Reata with the Lynch group at Children’s Hospital of Philadelphia (Lynch et al., 2021).
  • Alternative dose range: dose-finding identified 80–160 mg/day as optimal for biological response (Lynch et al., 2019); a pediatric trial is testing 250 mg (NCT06953583). Neither alternative is approved.
  • Reduced doses: 100 mg with moderate liver impairment or moderate CYP3A4 inhibitors; 50 mg with strong CYP3A4 inhibitors or if adverse reactions emerge (Skyclarys prescribing information).
  • Longevity use: no practitioner, clinic or trial has published an omaveloxolone regimen for healthy adults; dietary Nrf2 activators such as sulforaphane are an unrelated, unapproved alternative approach with their own separate evidence base.
  • Time of day: any consistent time on an empty stomach; morning, at least 1 hour before breakfast, is a common choice.
  • Half-life: about 57 hours (Skyclarys prescribing information), so blood levels build over roughly two weeks and a single missed dose changes them little.
  • Single versus split dose: a single daily dose; split dosing has not been studied. Missed doses are skipped, not doubled (Skyclarys prescribing information).
  • Swallowing difficulty: capsule contents sprinkled on applesauce gave equivalent exposure (Hynes et al., 2024, manufacturer-run); the label excludes milk and orange juice (Skyclarys prescribing information).
  • Genetic factors: no pharmacogenetic dose guidance exists; GAA1 repeat length informs disease severity, not dose.
  • Sex: no sex-based dose difference; exposure is similar (Skyclarys prescribing information). The label calls for a non-hormonal method in women using hormonal contraception.
  • Age: same dose from age 16 onward; adults over 65 were not studied, so closer liver, lipid and heart monitoring is common practice.
  • Baseline biomarkers: baseline ALT, AST, bilirubin, BNP and lipids determine whether to start and anchor later comparisons (Skyclarys prescribing information).
  • Pre-existing conditions: liver impairment changes the dose; heart disease, diabetes and pes cavus may change response or require closer follow-up.

Discontinuation & Cycling

  • Intended duration: long-term, continuous use for a progressive disease; controlled data cover 48 weeks and extension data about 3 years (Lynch et al., 2024).
  • Withdrawal effects: no withdrawal syndrome has been reported; liver enzymes and cholesterol return to baseline within about 4 weeks of stopping (Lynch et al., 2021; Skyclarys prescribing information). Whether neurological gains fade after stopping is unknown.
  • Tapering: no taper is required or studied; the long half-life provides a gradual decline. Restarting after a liver-related pause uses stepwise dose increases (Perlman et al., 2025).
  • Cycling: not studied; all trials used continuous daily dosing, and the benefit modeled is slowing of ongoing decline.
  • After stopping: non-hormonal contraception continues for 28 days (Skyclarys prescribing information).

Sourcing and Quality

  • Approved product: Skyclarys 50 mg capsules, marketed by Biogen, are the approved form (Skyclarys prescribing information). It is dispensed through specialty pharmacies.
  • Research-chemical sellers: “RTA-408” sold online for laboratory use has no verified purity, dose or sterility and is not intended for people; third-party testing does not exist for these materials.
  • What to look for: the light green and blue capsule imprinted “RTA 408” and “50”, in a sealed bottle of 90 (Skyclarys prescribing information).
  • Formulation: immediate-release capsules with standard fillers; contents may be sprinkled on applesauce but must not be crushed or chewed.
  • Storage: room temperature, 20–25 °C (68–77 °F) (Skyclarys prescribing information).

Practical Considerations

  • Time to effect: neurological differences emerged over months and were measured at 48 weeks; side effects and liver enzyme rises appear within the first 12 weeks (Lynch et al., 2021).
  • Common pitfalls: dosing with food, missing interacting medications or grapefruit, relying on hormonal contraception, skipping monthly liver tests, and expecting reversal rather than slower decline.
  • Regulatory status: prescription-only; FDA-approved in February 2023 and EU-authorized in February 2024 for Friedreich’s ataxia from age 16 (FDA approval announcement; European Medicines Agency product page). Use for longevity would be off-label and unsupported.
  • Cost and access: the U.S. wholesale acquisition cost was set at $370,000 at launch (Managed Healthcare Executive); coverage typically depends on a confirmed diagnosis, making longevity use practically inaccessible.
  • Payer incentives: with cheaper supportive care the only alternative, insurers and national health systems have a financial incentive to restrict coverage, which can shape reimbursement reviews and access as much as the evidence does.

Interaction with Foundational Habits

  • Sleep: no direct interaction is reported; insomnia was not a trial signal. Fatigue during the first 12 weeks may change daytime energy, an indirect effect; dosing time can be chosen to fit a regular sleep schedule.
  • Nutrition: direct interaction. The label requires dosing at least 1 hour before or 2 hours after eating and excludes grapefruit (Skyclarys prescribing information). Because LDL-C rises, a diet low in saturated fat and rich in fiber may offset part of it, and adequate protein counters appetite and weight loss.
  • Exercise: potentiating, possibly. MOTOR found lower heart rate and lactate during moderate exercise without higher peak capacity (Madsen et al., 2020). Exercise itself activates Nrf2; whether combining them helps or blunts training adaptation is untested (theoretical).
  • Stress management: no known interaction; no effect on cortisol or stress response has been studied. The disease’s psychological burden makes stress care relevant independently of the medication.

Monitoring Protocol & Defining Success

Before starting, the label calls for ALT, AST, total bilirubin, BNP and a lipid panel (Skyclarys prescribing information). Common practice adds ApoB, body weight, an echocardiogram (heart ultrasound) given the disease’s heart involvement, and a baseline mFARS exam so later decline can be judged against the individual’s own starting point. Pregnancy status and contraception are confirmed at the same visit.

Ongoing monitoring follows this cadence: liver tests at 1, 2 and 3 months, then periodically, with experts accepting less frequent testing once results stay normal (Perlman et al., 2025), commonly every 3–6 months; lipids and ApoB at 2–3 months, then every 6–12 months; weight monthly; BNP whenever swelling, breathlessness or rapid weight gain appear; mFARS and echocardiogram every 6–12 months. Success means a slower rate of mFARS worsening than before treatment, without liver, lipid or heart-strain problems.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT Lab-specific upper limit of normal, commonly about 7–55 U/L (standard reference range) Safety check: stop or pause if elevated Stop above 5× upper limit of normal, or above 3× with bilirubin rise (label); peaks in first 12 weeks; no fasting needed
AST Lab-specific upper limit of normal, commonly about 8–48 U/L (standard reference range) Safety check: stop or pause if elevated Pair with ALT and bilirubin; intense exercise in the prior 48 hours can raise AST
Total bilirubin About 0.1–1.2 mg/dL (standard reference range) Safety check: rise alongside ALT signals liver injury Omaveloxolone slightly lowers bilirubin (Lynch et al., 2021); a rise is therefore notable
BNP Below 100 pg/mL (standard reference range; label upper limit of normal) Safety check: rise may signal fluid overload Trial excluded BNP above 200 pg/mL (label); NT-proBNP is an acceptable alternative
LDL-C and HDL-C No established target; track change from own pre-treatment baseline Expected to change: LDL-C rises, HDL-C dips Mean LDL-C rise 23.5 mg/dL at 48 weeks (label); fasting sample preferred for consistency
ApoB No established target; track change from own pre-treatment baseline Expected to change: rises with LDL-C Rose 20–25 mg/dL in a real-world cohort (Buchinger et al., 2026); pair with lipid panel
mFARS score No established target; track yearly change against own baseline Expected to change: slower worsening defines benefit Matched untreated patients worsened 6.6 points over 3 years (Lynch et al., 2024); same examiner and time of day reduce noise
Body weight No established target; track change from own baseline Safety check: rapid gain suggests fluid overload; loss suggests poor intake Rapid gain threshold 3 lb/day or 5 lb/week (label); weigh same time, fasting
Left ventricular ejection fraction About 52–74% (standard reference range) Safety check: decline may stop or change use Trial required at least 40% (label); measured by echocardiogram

Qualitative markers:

  • Balance, falls and walking confidence
  • Speech clarity and swallowing ease
  • Hand coordination for tasks such as writing or buttoning
  • Daily energy and fatigue, especially in the first 12 weeks
  • Stomach comfort, appetite and headache frequency
  • Ankle swelling or breathlessness as possible fluid signs

Emerging Research

  • Pediatric efficacy trial: a Phase 3 randomized placebo-controlled trial in 255 children aged 2–15, primary endpoint the mFARS upright-stability subscore at week 52, then 150 versus 250 mg (NCT06953583). A positive result would add a second, though sponsor-run, randomized confirmation of slowed decline; a null result would weaken confidence in that benefit.
  • Long-term safety registry: an observational post-marketing registry of 300 treated patients tracking serious adverse events, drug-induced liver injury and heart failure for up to 5 years, completing 2029 (NCT06623890). Few events would ease liver and heart concerns; excess events would upgrade those risks.
  • Pediatric drug levels and growth: a Phase 1 open-label study of 33 children aged 2–15 tracking drug levels, growth and puberty, completing 2030 (NCT06054893). Normal growth would support younger use; growth or puberty effects would add a new risk.
  • Brain glutathione imaging: magnetic resonance spectroscopy (a scanner-based chemical measurement) of brain glutathione and GABA (the main calming brain messenger) before and after treatment in children aged 8–15, versus untreated healthy children (60 in total), completing 2030 (NCT07635030). A rise would show it reaches brain targets; no change would weaken the mechanistic rationale.
  • Pregnancy surveillance: a registry of births after exposure, primary outcome major birth defects, completing 2035 (NCT06628687). No excess defects would temper animal-based concern; an excess would confirm it.
  • Swallowing study: a retrospective French cohort of 40 patients using a swallowing questionnaire after 6 months (NCT07013292); its registered June 2026 completion has passed, it is still listed as recruiting, and no results are posted. Improvement would add a patient-relevant benefit; no change would not.
  • Long-term lipid and cardiovascular effects: a Vienna cohort found a sustained, atherogenic (artery-clogging) rise in LDL-C and ApoB (Buchinger et al., 2026); larger, longer studies could either confirm a cardiovascular cost or show it is offset.
  • Real-world effectiveness: pooled real-world cohorts still worsened, though more slowly than the disease’s untreated course predicts (Ali et al., 2026); longer registries will test whether benefit persists outside trials.
  • Other diseases: cell and fly models of spinocerebellar ataxia type 3 (another inherited ataxia) (Pan et al., 2026) and rodent pulmonary hypertension (high pressure in the lung arteries) (Huang et al., 2026) suggest wider uses, while Nrf2’s cancer-shielding role (Lau et al., 2008) argues caution.
  • Healthy aging: no registered trial tests omaveloxolone in healthy adults or on aging markers; such a trial would be the first direct evidence for or against longevity use.

Conclusion

Omaveloxolone is a prescription oral medication that turns on the body’s own antioxidant and anti-inflammatory defense system. Its established use is narrow: it is the first approved treatment for Friedreich’s ataxia, where controlled evidence points to a modest slowing of neurological decline and a smaller, less certain effect on daily function. That evidence comes mainly from one research group’s trials funded by the manufacturer, longer-term comparisons rely on outside untreated patients rather than random assignment, and pooled reviews and early real-world groups paint a less clear picture. The size and durability of the benefit therefore remain uncertain.

The main risks are fairly well described for a recent medication: frequent, usually reversible rises in liver enzymes, higher harmful cholesterol, more frequent rises in a heart-strain blood marker, and early stomach upset, headache and tiredness. It interacts with many common medications through the liver’s main drug-clearing system and can make hormonal birth control unreliable. Animal studies leave open questions about pregnancy, liver tumors and whether long-term switching on of this defense system could also protect cancer cells.

For health-focused adults without Friedreich’s ataxia, no human evidence shows benefit for aging, lifespan or performance; the appeal rests on animal and cell biology. Set against that are real monitoring demands, a very high price that gives insurers reason to limit access, and measurable harms, so for a healthy adult the balance currently rests on biological plausibility alone.

Top - Benefits - Risks - Protocol